1. Home
  2. NAMS vs BFH Comparison

NAMS vs BFH Comparison

Compare NAMS & BFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • BFH
  • Stock Information
  • Founded
  • NAMS 2019
  • BFH 1996
  • Country
  • NAMS Netherlands
  • BFH United States
  • Employees
  • NAMS N/A
  • BFH N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • BFH Business Services
  • Sector
  • NAMS Health Care
  • BFH Consumer Discretionary
  • Exchange
  • NAMS Nasdaq
  • BFH Nasdaq
  • Market Cap
  • NAMS 2.5B
  • BFH 2.3B
  • IPO Year
  • NAMS N/A
  • BFH N/A
  • Fundamental
  • Price
  • NAMS $23.60
  • BFH $63.27
  • Analyst Decision
  • NAMS Strong Buy
  • BFH Hold
  • Analyst Count
  • NAMS 9
  • BFH 14
  • Target Price
  • NAMS $41.11
  • BFH $60.08
  • AVG Volume (30 Days)
  • NAMS 844.8K
  • BFH 671.8K
  • Earning Date
  • NAMS 08-06-2025
  • BFH 07-24-2025
  • Dividend Yield
  • NAMS N/A
  • BFH 1.32%
  • EPS Growth
  • NAMS N/A
  • BFH N/A
  • EPS
  • NAMS N/A
  • BFH 5.80
  • Revenue
  • NAMS $47,140,000.00
  • BFH $2,452,000,000.00
  • Revenue This Year
  • NAMS N/A
  • BFH $60.92
  • Revenue Next Year
  • NAMS N/A
  • BFH $4.20
  • P/E Ratio
  • NAMS N/A
  • BFH $10.95
  • Revenue Growth
  • NAMS 586.97
  • BFH N/A
  • 52 Week Low
  • NAMS $14.06
  • BFH $38.21
  • 52 Week High
  • NAMS $27.29
  • BFH $66.71
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 67.01
  • BFH 61.29
  • Support Level
  • NAMS $22.00
  • BFH $60.66
  • Resistance Level
  • NAMS $24.82
  • BFH $64.65
  • Average True Range (ATR)
  • NAMS 1.21
  • BFH 1.90
  • MACD
  • NAMS 0.25
  • BFH -0.10
  • Stochastic Oscillator
  • NAMS 77.98
  • BFH 74.91

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About BFH Bread Financial Holdings Inc.

Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private-label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains a minority interest in spun-off LoyaltyOne, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.

Share on Social Networks: